Role of amino acid residue 90 in bioactivity and receptor binding capacity of tumor necrosis factor mutants.

[1]  Y. Yoshioka,et al.  Functionalization of Tumor Necrosis Factor-α Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window , 2004, Clinical Cancer Research.

[2]  Yasuo Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.

[3]  Y. Yoshioka,et al.  Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting , 2003, Nature Biotechnology.

[4]  F. Lejeune.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. , 2002, The Journal of clinical investigation.

[5]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[6]  Y. Tsutsumi,et al.  Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice , 2000 .

[7]  C. Rüegg,et al.  Clinical applications of TNF-α in cancer , 1998 .

[8]  H. Michel,et al.  Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. , 1997, Analytical biochemistry.

[9]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Banner,et al.  Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. , 1993, The Journal of biological chemistry.

[11]  W. Furman,et al.  Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Yamada,et al.  Mutational analysis of structure--activity relationships in human tumor necrosis factor-alpha. , 1990, Protein engineering.

[13]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[14]  W. Fiers,et al.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity , 1988, The Journal of experimental medicine.

[15]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Takashi,et al.  Antitumor Activity of Tumor Necrosis Factor a Conjugated with Divinyl Ether and Maleic Anhydride Copolymer on Solid Tumors in Mice' , 2006 .

[17]  T. Taguchi,et al.  Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[18]  N. Niederle,et al.  Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease , 2004, Cancer Immunology, Immunotherapy.

[19]  Y. Tsutsumi,et al.  PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency , 1997, Thrombosis and Haemostasis.

[20]  E. Eisenhauer,et al.  A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[21]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Helson,et al.  Effects of murine tumor necrosis factor on heterotransplanted human tumors. , 1979, Experimental cell biology.